Skip to main content
Terug
PGEN logo

Precigen, Inc.

Datakwaliteit: 100%
PGEN
NASDAQ Healthcare Biotechnology
€ 3,13
▼ € 0,11 (-3,40%)
Marktkapitalisatie: 940,34M
Dagbereik
€ 3,05 € 3,23
52-Weeksbereik
€ 1,11 € 5,47
Volume
5.144.758
50D / 200D Gem.
€ 4,17 / € 3,40
Vorige Slotkoers
€ 3,24

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -7,5 0,4
P/B 24,4 2,9
ROE % -160,8 3,9
Net Margin % -3216,2 3,8
Rev Growth 5Y % -40,8 10,0
D/E 0,1 0,2

Koersdoel Analisten

Hold
€ 6,00 +91.7%
Forward WPA
-€ 0,18
Omzet Sch.
99 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2029 € 0,63
€ 0,49 – € 0,77
450 M 1
FY2028 € 0,38
€ 0,30 – € 0,47
330 M 1
FY2027 € 0,07
-€ 0,01 – € 0,16
210 M 2

Belangrijkste Punten

Revenue declined -40,82% annually over 5 years
Debt/Equity of 0,14 — conservative balance sheet
Negative free cash flow of -76,76M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3,87%
Capital intensive — 218,70% of revenue goes to capex

Groei

Revenue Growth (5Y)
-40,82%
Revenue (1Y)-36,95%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-160,80%
ROIC-230,08%
Net Margin-3216,18%
Op. Margin-3440,23%

Veiligheid

Debt / Equity
0,14
Current Ratio4,76
Interest Coverage-22504,83

Waardering

P/E Ratio
-7,45
P/B Ratio24,42
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -36,95% Revenue Growth (3Y) -61,81%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -40,82% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 3,93M Net Income (TTM) -126,24M
ROE -160,80% ROA -86,90%
Gross Margin -8,71% Operating Margin -3440,23%
Net Margin -3216,18% Free Cash Flow (TTM) -76,76M
ROIC -230,08% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,14 Current Ratio 4,76
Interest Coverage -22504,83 Dividend Yield 0,00%
Valuation
P/E Ratio -7,45 P/B Ratio 24,42
P/S Ratio 239,58 PEG Ratio -0,12
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 940,34M Enterprise Value 916,33M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 3,93M 6,23M 26,91M 14,27M 31,99M
Net Income -126,24M -95,90M 28,32M -92,17M -170,52M
EPS (Diluted) -0,47 -0,39 -0,33 -0,47 -1,02
Gross Profit -342.000,0 106.000,0 20,57M -39,41M -12,81M
Operating Income -135,03M -99,76M -75,73M -91,95M -86,32M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 145,27M 151,04M 215,98M 359,86M 314,59M
Total Liabilities 106,75M 32,55M 89,72M 252,51M 247,41M
Shareholders' Equity 38,51M 118,50M 126,26M 107,35M 67,17M
Total Debt 5,50M 7,10M 51,42M 190,07M 182,28M
Cash & Equivalents 29,52M 7,58M 4,86M 36,42M 51,79M
Current Assets 102,41M 68,76M 118,16M 156,63M 148,95M
Current Liabilities 21,52M 22,99M 78,65M 34,65M 42,13M